2004
DOI: 10.18597/rcog.594
|View full text |Cite
|
Sign up to set email alerts
|

El síndrome de la plaqueta pegajosa: serie de casos en gestantes en el hospital militar central y revisión de literatura

Abstract: El síndrome de la plaqueta pegajosa es un desorden plaquetario autosómico dominante asociado con eventos tromboembólicos arteriales y venosos. Se caracteriza por hiperagregabilidad plaquetaria en plasma rico en adenosindifosfato y epinefrina. Clínicamente las pacientes pueden presentar angina de pecho, infarto agudo del miocardio, accidentes isquémicos transitorios, accidentes cerebrovasculares, trombosis retiniana, trombosis de arterias periféricas y trombosis venosas, frecuentemente recurrente bajo tratamien… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
2
0
2

Year Published

2016
2016
2021
2021

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 11 publications
0
2
0
2
Order By: Relevance
“…1 In this cohort, we recorded gender, type of SPS, type of thrombotic events, number of thrombotic events, and localization of the thrombosis (Table 1). All patients had a proven (angiography or doppler ultrasound) thrombotic episode and one of the clinical markers of a primary thrombophilic condition 1, 5,7–11 : (a) family history of thrombosis, (b) thrombosis at uncommon anatomic locations, and (c) resistance to conventional antithrombotic therapy. The SPS was defined by specific laboratory methods described by Mammen et al, 4,12,13 Kubisz et al, 6,7,14 and Ruiz-Delgado et al 1 Patients with clinical conditions related to secondary thrombophilia were excluded, as well as patients who had other inherited thrombophilic in addition to the SPS.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…1 In this cohort, we recorded gender, type of SPS, type of thrombotic events, number of thrombotic events, and localization of the thrombosis (Table 1). All patients had a proven (angiography or doppler ultrasound) thrombotic episode and one of the clinical markers of a primary thrombophilic condition 1, 5,7–11 : (a) family history of thrombosis, (b) thrombosis at uncommon anatomic locations, and (c) resistance to conventional antithrombotic therapy. The SPS was defined by specific laboratory methods described by Mammen et al, 4,12,13 Kubisz et al, 6,7,14 and Ruiz-Delgado et al 1 Patients with clinical conditions related to secondary thrombophilia were excluded, as well as patients who had other inherited thrombophilic in addition to the SPS.…”
Section: Methodsmentioning
confidence: 99%
“…1,47 The clinical manifestations involve venous and arterial thrombosis, fetal loss, and fetal growth retardation. 1,3,6,8,9 In this study, we analyze the localization of both the arterial and venous thrombotic events in a cohort of Mexican mestizo patients with the SPS.…”
Section: Introductionmentioning
confidence: 99%
“…Las trombofilias, definidas como la tendencia a desarrollar fenómenos de trombosis arterial o venosa recurrente, espontáneas o con mínima provocación, a edades menores de las habituales, en territorios poco comunes ya sea de origen congénito o adquirido [166,167], en los últimos años se han documentado como causa íntima de pérdidas fatales recurrentes [168][169][170][171][172]. Dentro las trombofilias congénitas asociadas con pérdidas fetales recurrentes la que más se ha encontrado en nuestro medio [173,174] y en otros países latinoamericanos [175][176][177] es el síndrome de plaqueta pegajosa situación que se controla efectivamente con aspirina a bajas dosis. Como en todos los casos anteriores, en estas pacientes el tratamiento con aspirina puede presentar resistencia y por lo tanto no ser suficiente para el manejo de la perdida fetal, de ahí la importancia del seguimiento a través de pruebas de laboratorio, como las analizadas en este módulo.…”
Section: Aspirina Y Pérdidas Fetalesunclassified
“…Sexo femenino [108,110,112,170,171] Edad avanzada [110,112,172] Biodisponibilidad de la aspirina Consumo a las dosis y en las condiciones inadecuadas [173][174][175] Uso de aspirina con capa entérica [176] Consumo concomitante con otros medicamentos (p. ej. antiinflamatorios no esteroideos (AINEs) [177,178], ibuprofeno [179], indometacina, naproxeno [177,180,181], inhibidores de la bomba de protones [78,176,[182][183][184][185])…”
Section: Factores Demográficosunclassified